Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Gilead Provides Expanded Access Program for Tenofovir

March 2001

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Gilead Sciences, the developers of a new nucleotide analogue, tenofovir (PMPA), started a small expanded access program in January.

The most important use of this drug, for now, will probably be in people who have developed resistance to several of the NRTI drugs, like d4T (Zerit) and AZT (Retrovir), and need something new to shore up their combination therapy. It is less clear whether the drug will compensate for protease inhibitor failure. The initial program will begin small and expand during 2001 as drug supplies increase.

To qualify, people must have all of the following:

  • Over 10,000 copies HIV RNA and CD4+ cell counts below 100 or CD4+ cell counts below 200 and an opportunistic infection within the past three months;

    Advertisement

  • Intolerance to and/or viral load increases to at least two protease inhibitors or one protease inhibitor and one NNRTI (for a list of the names and types of anti-HIV drugs, call Project Inform's Hotline); and

  • Unable to construct a viable drug combination without tenofovir.

To register patients in the program, physicians should call 800-GILEAD-5 (800-445-3235).

As more drug supplies become available, the criteria to qualify will change.


Back to the Project Inform Perspective March 2001 contents page.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on Tenofovir (Viread)

Tools
 

Advertisement